文献速递胸部肿瘤

老年晚期非小细胞肺癌卡铂联合周疗紫杉醇诱导后切换维持化疗对比观察:IFCT-1201 MODEL随机试验

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
PubMed 文献 · Eur J Cancer · 2020-09-06

IFCT-1201 MODEL试验纳入70-89岁晚期非小细胞肺癌患者,在四周期卡铂联合周疗紫杉醇诱导未进展后随机比较切换维持化疗(非鳞癌用培美曲塞,鳞癌用吉西他滨)与观察。共632例入组,328例随机;结论:切换维持化疗不应推荐用于老年晚期NSCLC患者。

要点

  • 老年晚期NSCLC诱导未进展后,切换维持化疗显著延长PFS但未延长OS。
  • 维持组中位PFS 5.7个月 vs 观察组2.7个月,p<0.001,差异显著。

核心结论

  • 在70-89岁晚期非小细胞肺癌患者中,诱导治疗后切换维持化疗显著延长无进展生存期,但未延长总生存期,不应推荐用于该人群。

研究设计与样本

  • 随机对照试验,纳入70-89岁、无EGFR突变及ALK重排、四周期卡铂联合周疗紫杉醇诱导后未进展的晚期NSCLC患者。
  • 632例入组,328例(52.3%)随机;观察组166例,切换维持组162例(培美曲塞119例,吉西他滨43例)。
  • 入组要求体能状态评分0-2、简易智力评分>23、肌酐清除率≥45 mL/min。
  • 主要终点为总生存期。

主要发现

  • 自随机化起中位无进展生存期:观察组2.7个月(95%CI 2.6-3.1),维持组5.7个月(95%CI 4.8-7.1),p<0.001。

关键数值与推荐

  • 非鳞状细胞癌维持方案:培美曲塞500 mg/m²,第1、22天给药。
  • 鳞状细胞癌维持方案:吉西他滨1,150 mg/m²,第1、8、22天给药。
  • 诱导方案:每月卡铂联合周疗紫杉醇,共四周期。

临床怎么用

  • 对于70-89岁晚期NSCLC患者,诱导化疗未进展后不建议常规给予切换维持化疗,因总生存期未获益。
  • 切换维持化疗可延长无进展生存期,但需权衡老年患者耐受性及缺乏生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Maintenance chemotherapy is a reasonable choice for patients with metastatic non-small cell lung carcinoma (NSCLC) not progressing after induction therapy with a platinum-based doublet. Nevertheless, there have been no studies dedicated to elderly patients. PATIENTS AND METHODS: We conducted a randomised trial in patients aged 70-89 years, with advanced NSCLC (with neither EGFR mutation nor ALK rearrangement), who had not progressed after four cycles of monthly carboplatin and weekly paclitaxel in order to compare maintenance with either pemetrexed (500 mg/m2 d1, 22) in patients with non-squamous cell carcinoma or gemcitabine (1,150 mg/m2 d1, 8, 22) in squamous cell carcinoma to simple observation. The patients were required to have a performance status (PS) 0-2, mini-mental score >23, and creatinine clearance ≥45 mL/min. The primary end-point was overall survival (OS). RESULTS: 632 patients were enrolled from May 2013 to October 2016. Of the 328 (52.3%) patients randomised after induction therapy, 166 patients were assigned to the observation arm, versus 162 to the switch maintenance arm, 119 of whom received pemetrexed and 43 gemcitabine. The median OS from randomisation was 14.1 months (95% confidence interval [CI]: 12.0-17.0) in the observation arm and 14 months (95% CI: 10.9-16.9) in the maintenance arm (p = 0.72). The median progression-free survival (PFS) from randomisation was 2.7 months (95% CI: 2.6-3.1) in the observation arm versus 5.7 months (95% CI: 4.8-7.1) in the maintenance arm (p < 0.001). CONCLUSION: Switch maintenance therapy significantly prolonged PFS but not OS and, thus, should not be proposed to elderly patients with advanced NSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Quoix E, Audigier-Valette C, Lavolé A, et al. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial. Eur J Cancer. 2020. PMID: 32898792. doi:10.1016/j.ejca.2020.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。